DDInter255 DDInter165
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022.
Busulfan {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Baricitinib
Busulfan {u} (Compound) upregulates {v} (Gene) HLA-DRA
HLA-DRA {u} (Gene) is upregulated by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Busulfan {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Busulfan {u} (Compound) downregulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Busulfan {u} (Compound) upregulates {v} (Gene) HLA-DRA
HLA-DRA {u} (Gene) is upregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Busulfan {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Busulfan {u} (Compound) downregulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Procarbazine
Procarbazine {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Busulfan {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Busulfan {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Hydromorphone
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Busulfan (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Busulfan (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Busulfan (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound) and Etoposide may lead to a major life threatening interaction when taken with Baricitinib
Busulfan (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Busulfan (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Baricitinib
Busulfan (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Busulfan (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Procarbazine (Compound) and Procarbazine may lead to a major life threatening interaction when taken with Baricitinib
Busulfan (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Baricitinib
Busulfan (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Baricitinib
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib